BioMarin Pharmaceuticals, Inc. (BMRN)

Company Description

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company’s product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan(R) (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse(TM) (amifampridine), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include BMN-110 (N-acetylgalactosamine 6-sulfatase), formally referred to as GALNS, which successfully completed Phase III clinical development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease, BMN-673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers, and BMN-111, a modified C-natriuretic peptide, which is currently in Phase I clinical development for the treatment of achondroplasia.

105 Digital Drive
Novato, CA 94949
United States



Get BioInvest's perspective on BioMarin's CEO

Latest Company News

Stock Price of BioMarin Pharmaceutical Inc. (BMRN) Decreases -0.29% Highland Mirror - Feb 21, 2017 BioMarin Pharmaceutical Inc.s chart and data analysis indicates that the stock price has rallied 0.98% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -6 ... Smart Money Buying the Price Weakness of BioMarin Pharmaceutical Inc. (BMRN) - Money Flow Index & Trends The Baird Financial Group Inc. Raises Position in BioMarin Pharmaceutical Inc ... - DailyQuint [...]
Tue, Feb 21, 2017 9:45:00 AM, Continue reading at the source
Better Buy: Alnylam Pharmaceuticals, Inc. vs. BioMarin Pharmaceutical Inc. Motley Fool - Feb 20, 2017 Meanwhile, plenty of clinical-stage programs at Biomarin Pharmaceutical Inc. (NASDAQ:BMRN) have been chugging along without much drama, but the stock is looking mighty expensive lately. [...]
Mon, Feb 20, 2017 1:41:00 PM, Continue reading at the source
BioMarin (BMRN) Q4 Earnings: Will it Post a Beat Again? Yahoo Finance - Feb 17, 2017 We expect BioMarin Pharmaceutical Inc. BMRN to beat expectations when it reports fourth-quarter and full-year 2016 results on Feb 23 after the market closes. Analyst's Indicator Review for BioMarin Pharmaceutical Inc. (BMRN), Intuit Inc ... - The USA Commerce Today's Brokerage Rating: BioMarin Pharmaceutical Inc. (BMRN), Dollar General ... - StockNewsJournal [...]
Fri, Feb 17, 2017 12:11:00 PM, Continue reading at the source
BioMarin Pharmaceutical Inc. (BMRN) Moves Lower on Volume Spike for February 16 - Feb 16, 2017 BioMarin Pharmaceutical Inc. (BMRN) traded on unusually high volume on Feb. 16, as the stock lost 1.04% to close at $90.53. EPS Target Of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Set At $0.27 - Transcript Daily Yesterday's Consideration Movers: Skyworks Solutions Inc. (NASDAQ:SWKS ... - TRA [...]
Thu, Feb 16, 2017 10:30:00 PM, Continue reading at the source
BioMarin Announces 11 Presentations at 13th Annual WORLDSymposium™ 2017 PR Newswire (press release) - Feb 15, 2017 SAN RAFAEL, Calif., Feb. 15, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the company will present data in four oral and seven poster presentations at the 13th Annual WORLDSymposium™ being held ... [...]
Wed, Feb 15, 2017 1:30:00 PM, Continue reading at the source
Morgan Stanley Starts BioMarin Pharmaceutical Inc. (BMRN) at Overweight - Feb 7, 2017 Morgan Stanley initiates coverage on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) with a Overweight rating and a price target of $110.00. BioMarin sues to stop generic version of its $90Ka-year drug - San Francisco Business Times Stock Returns: BioMarin Pharmaceutical Inc (NASDAQ:BMRN) is Beating Opko ... - CML News [...]
Tue, Feb 07, 2017 8:48:00 AM, Continue reading at the source
Trading Options During Earnings in BioMarin Pharmaceutical Inc (NASDAQ:BMRN) CML News - Jan 14, 2017 We're going to examine buying and selling out of the money strangles in BioMarin Pharmaceutical Inc and find out once and for all what the winning trades have been during earnings releases. [...]
Sat, Jan 14, 2017 7:41:00 PM, Continue reading at the source
BioMarin Pharmaceutical (BMRN) Q3 2016 Results - Earnings Call Transcript Seeking Alpha - Oct 28, 2016 Good afternoon, ladies and gentlemen, and welcome to the BioMarin Pharmaceutical, Inc. Conference Call to discuss Third Quarter 2016 Financial Results. BioMarin's Disappointing 3Q16 Earnings - Market Realist [...]
Fri, Oct 28, 2016 7:04:00 AM, Continue reading at the source
Solid BioMarin Pharmaceutical Inc. Earnings, More to Come Motley Fool - Aug 10, 2016 BioMarin Pharmaceuticals (NASDAQ:BMRN) reported second-quarter earnings last week. While the biotech's current drugs are still growing at a nice pace, it's BioMarin's pipeline, including two drugs that have already read out positive phase 3 data, that ... Investors Snatch BMRN 5.6% Cheaper Than Its Secondary Stock Offering - Forbes BioMarin Pharma's (BMRN) 7.5M Common Stock Offering Prices at $96/Share - [...]
Wed, Aug 10, 2016 7:52:00 PM, Continue reading at the source
Why BioMarin Pharmaceutical Inc. Stock Rose 22.2% in July Motley Fool - Aug 6, 2016 What: Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), a biopharmaceutical company focused on diseases with unmet need, gained 22.2% in July, according to data from S&P Global Market Intelligence. BioMarin: The Tesla Of Biotech - Seeking Alpha [...]
Sat, Aug 06, 2016 4:43:00 PM, Continue reading at the source